Minimally invasive biomarker confirms glial activation present in Alzheimer’s disease: a preliminary study

Napapon Sailasuta
Kent Harris
Thao Tran
Brian Ross
Clinical MR Unit, Huntington Medical Research Institutes, Pasadena, CA, USA

Abstract: We applied $^{13}$C magnetic resonance spectroscopy (MRS), a nonradioactive, noninvasive brain imaging technique, to quantify the oxidation of $[1-^{13}$C] acetate in a conventional clinical magnetic resonance imaging (MRI) scanner in five consecutive elderly subjects at various clinical stages of Alzheimer’s disease (AD) progression. $[1-^{13}$C] acetate entered the brain and was metabolized to $[5-^{13}$C] glutamate and glutamine, as well as $[1-^{13}$C] glutamate and glutamine, and the final glial oxidation product, $^{13}$C bicarbonate, at a linear rate. Calculation of the initial slope was similar in a single subject, examined twice, 1 month apart (test-re-test 8%). Mean rate of cerebral bicarbonate production in this elderly group was 0.040 ± 0.01 (n = 5). Assuming that the rate of conversion of acetate to bicarbonate is a reflection of glial metabolic rate and that glial metabolic rate is a surrogate marker for ‘neuroinflammation’, our preliminary results suggest that $[1-^{13}$C] MRS may provide biomarkers for diseases, believed to involve microglia and other cells of the astrocyte series. Among these is AD, for which novel drugs which ameliorate the damaging effects of neuroinflammation before symptoms of dementia appear, are in advanced development. The value of $^{13}$C MRS as an early, noninvasive biomarker may lie in the conduct of cost-effective clinical trials.

Keywords: Alzheimer’s disease, noninvasive biomarker, glial activation

Introduction

In Alzheimer’s disease (AD), incidence and prevalence increase with age. AD is the sixth leading cause of death in the US, and there are no effective therapies for the disease. Development of disease-modifying treatments for AD has been both expensive and unsuccessful to date. A shortcoming of current largely neuronal biomarkers, magnetic resonance imaging (MRI), amyloid imaging, and cerebrospinal fluid biomarkers, is the absence of an accepted biomarker for glial activation.\(^1,\(^2\) Neuroinflammation, also termed glial activation, has long been implicated in the pathology of AD.\(^3\) Recent research has shown that there are early pathological changes in the brains of persons with predementia memory decline, which can even be detected in asymptomatic individuals who may eventually develop AD.\(^4,\(^5\) This phenomenon occurs early in the course of AD possibly before the more extensive neuron damage monitored by clinical tests. Most AD clinical trials depend on measures of rates of change in highly variable and insensitive clinical and cognitive measures. Therefore, there is an urgent need for appropriate biomarkers that can serve as outcome endpoints to detect progression of disease.

Magnetic resonance spectroscopy (MRS) is a powerful method for measuring brain metabolism. Noninvasive proton MRS has been used to measure brain chemical contents
statically\textsuperscript{6–8} while minimally invasive carbon MRS has been used to measure brain metabolic processes in action, dynamically.\textsuperscript{9} With appropriate infusion of brain exogenous labeled substrates, neuronal and glial metabolic rates have been reported in numerous neurodegenerative diseases.\textsuperscript{10–14} It is accepted that acetate, which enters the brain tricarboxylic acid cycle via an astrocyte-specific enzyme, can be used as a tracer for astrocyte or glial oxidative metabolism.\textsuperscript{15–17} Both C1 and C2 labeled acetate have been used successfully to study glial metabolism in intact human brains.\textsuperscript{10,13,14} In aging, evidence of upregulation of astrocytes (glia) metabolism was demonstrated with an increase of 25\% in older subjects compared with younger adults using labeled C2 acetate as exogenous substrate.\textsuperscript{18}

In this preliminary communication, we employed a short protocol developed previously\textsuperscript{19} to directly measure glial dysfunction in Alzheimer’s patients using C1 acetate as an exogenous labeled substrate.

## Methods

### Patients

The studies were approved by the local internal review board (Huntington Memorial Hospital), and all patients gave written informed consent. A total of 24 MRI/MRS studies were performed on six subjects of whom two had AD, two had mild cognitive impairment (MCI) and two were healthy older adults with mean age of 78±3 years, and two were females.

### Neuropsychological assessments

All subjects underwent extensive neuropsychological evaluation using the standard test battery to evaluate AD.\textsuperscript{20} Briefly: premorbid estimates of intellectual functioning were performed (Wechsler Test of Adult Reading). The core neuropsychological battery included the Wechsler Adult Intelligence Scales, third ed. (WAIS-III) and the Wechsler Memory Scales, third ed. (WMS-III) Domains of Attention/Concentration/Working Memory (WAIS-III Digit Span, Letter–Number Sequencing and Arithmetic), Psychomotor/Information processing (WAIS-III Symbol Search and Digit Symbol, Stroop word reading and color naming), Language functions (COWAT-FAS and Animals, WAIS-III Information), Verbal Memory (WMS-III Logical Memory I and II, California Verbal Learning Test-II), Nonverbal Memory (Brief Visual Memory Test-Revised, Rey Osterreich Complex Figure Test-Delay), Visuospatial/construction (WAIS-III Block Design, Picture Completion, Ruff Figural Fluency, Judgment of Line Orientation, Rey Osterreich Complex Figure Test-Copy) Executive Functions

### Table 1 Compilations of subjects’ characteristics, proton, carbon MRS, and neuropsychological assessment results

<table>
<thead>
<tr>
<th>Subject characteristics</th>
<th>Patient 1 Control</th>
<th>Patient 2 Control</th>
<th>Patient 3 MCI</th>
<th>Patient 4 MCI</th>
<th>Patient 5 AD</th>
<th>Patient 6 AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>80</td>
<td>83</td>
<td>77</td>
<td>81</td>
<td>76</td>
<td>76</td>
</tr>
<tr>
<td>Gender</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>MMSE</td>
<td>30</td>
<td>28</td>
<td>26</td>
<td>27</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>NAA/Cr</td>
<td>1.45</td>
<td>1.37</td>
<td>1.47</td>
<td>1.37</td>
<td>1.62</td>
<td>1.39</td>
</tr>
<tr>
<td>ml/Cr</td>
<td>0.56</td>
<td>0.72</td>
<td>0.77</td>
<td>0.74</td>
<td>0.85</td>
<td>0.83</td>
</tr>
<tr>
<td>NAA/ml</td>
<td>2.6</td>
<td>1.92</td>
<td>1.92</td>
<td>1.85</td>
<td>1.34</td>
<td>1.67</td>
</tr>
<tr>
<td>Rate of bicarbonate production (%FE/minute)</td>
<td>0.023</td>
<td>0.03</td>
<td>0.042</td>
<td>0.033</td>
<td>0.056</td>
<td>0.06</td>
</tr>
</tbody>
</table>

### Neuropsychological assessment (Z scores)

<table>
<thead>
<tr>
<th>Attention/concentration</th>
<th>WNL</th>
<th>WNL</th>
<th>–2</th>
<th>WNL</th>
<th>–1.6</th>
<th>–1.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Working memory</td>
<td>WNL</td>
<td>WNL</td>
<td>WNL</td>
<td>WNL</td>
<td>–1.5</td>
<td>–1.5</td>
</tr>
<tr>
<td>Psychomotor/Information processing</td>
<td>WNL</td>
<td>WNL</td>
<td>–1.5</td>
<td>WNL</td>
<td>–1.5</td>
<td>–1.5</td>
</tr>
<tr>
<td>Language functions</td>
<td>WNL</td>
<td>WNL</td>
<td>–1.3</td>
<td>WNL</td>
<td>–3</td>
<td>–3</td>
</tr>
<tr>
<td>Verbal memory</td>
<td>WNL</td>
<td>WNL</td>
<td>–3</td>
<td>WNL</td>
<td>–3</td>
<td>–3</td>
</tr>
<tr>
<td>Nonverbal memory</td>
<td>WNL</td>
<td>WNL</td>
<td>–3</td>
<td>WNL</td>
<td>–3</td>
<td>–3</td>
</tr>
<tr>
<td>Visuospatial/construction</td>
<td>WNL</td>
<td>WNL</td>
<td>–2</td>
<td>WNL</td>
<td>–2</td>
<td>–2</td>
</tr>
<tr>
<td>Executive functions</td>
<td>WNL</td>
<td>WNL</td>
<td>–1.4</td>
<td>WNL</td>
<td>–3</td>
<td>–3</td>
</tr>
<tr>
<td>Motor functions</td>
<td>WNL</td>
<td>WNL</td>
<td>–1.3</td>
<td>WNL</td>
<td>WNL</td>
<td>WNL</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer’s disease; Cr, creatine; FE, fractional enrichment; ml, myo-inositol; MCI, mild cognitive impairment; MMSE, mini-mental state examination; MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate; WNL, within normal range.
(Delis–Kaplan Executive Functions System – Tower Test), and Motor Functioning (Purdue Pegboard) were assessed.

All subjects underwent mini-mental state examination (MMSE). Criteria for MCI cut-off from normal included absence of dementia (MMSE ≥ 23) essentially preserved activities of daily living, the presence of cognitive and/or memory complaints, and impairment >1 standard deviation below age norms on one or more immediate or delayed memory tests or ≥2 nonmemory tests. Criteria for AD classification included MMSE score <23, impairment in activities of daily living, and ≥2 standard deviations below age norms on a majority of memory tests.

**Neuroimaging and spectroscopy**

Examinations were performed on a GE 1.5 T MRI scanner equipped with non-proton MRS capability as previously prescribed. Localized MRI was acquired with a 30-slice T2-weighted fast spin echo imaging sequence with echo time (TE) = 96 milliseconds, repetition time (TR) = 4 seconds, slice thickness = 5 mm, 1 excitation, and 256 × 192 data acquisition matrix using a single channel quadrature head coil for both transmitting and receiving. These localizer images were used to prescribe two single voxel proton MRS acquisitions of posterior cingulate grey matter and white matter (PROBE-p TE = 35 milliseconds, TR = 1.5 seconds, 8 mL voxel, 128 averages). For proton decoupled $^{13}$C MRS, scanning protocol is similar to that previously described. Briefly, prior to the start of the infusion protocol, a natural abundance $^{13}$C MRS was acquired for 30 minutes of five blocks pulse, to acquire data averaging a Waltz-4 bi-level proton decoupling and nuclear OverHouser (NOE) scheme with a power level of 5 W during decoupling and 0.9 W during the NOE period. Subsequently, intravenous administration of stable isotope enriched 1–13C acetate (Cambridge Isotopes Laboratories, Andover, MA; FDA IND 59,950) was performed with the subjects lying comfortably outside the MRI scanner for 60 minutes. The patients were then swiftly positioned back in the MRI scanner and data acquisition was performed for another 60 minutes.

**Data and statistical analysis**

Automated spectral processing for single voxel proton MRS data was performed using the commercially available LCModel software using a standard 1.5T reference basis set for semi-quantification. The results are reported as metabolic ratios.

For $^{13}$C MRS time series data were processed as previously described using an observer-independent automatic IDL-based software developed in house and SAGE (GE Healthcare, Milwaukee, WI). The rate of bicarbonate production was determined using the difference between the amount of measured bicarbonate level pre- and post-infusion over the time from the start of infusion to the end of data acquisition.

Simple statistical analysis was performed using linear regression, and the goodness of linear fit is reported as $R^2$.

**Results**

Subject characteristics, MRS, and neuropsychological evaluation results are shown in Table 1.

Proton MRS shows increased myoinositol to creatine ratio and decreased N-acetyl aspartate to myoinositol ratio,
similar to results previously reported. Typical proton MRS spectra in cognitively normal, MCI, and AD subjects are shown in Figure 1.

Glial metabolism of $^{13}$C acetate was demonstrated by increased $^{13}$C enrichment of cerebral bicarbonate (HCO$_3$, 161 ppm) compared with pre-infusion (Figure 2). The unenriched total creatine resonance (tCr, 158 ppm) was also observed. Clinically defined normal, MCI, and AD patients (MMSE normal = 28–30, MCI = 23–27, AD < 23) was accompanied by reduction in NAA/mI ($-36\% \pm 0.05; P = 0.01$) as previously described.

In contrast, $^{13}$C MRS showed a progressive increase in enrichment of the glial-oxidation product, $^{13}$C-bicarbonate (Figure 2). The increase in glial metabolic activity showed that %fractional enrichment of bicarbonate was inversely correlated with clinical grade (MMSE) ($R^2 = 0.908$) (Figure 3A) and MRS-glial biomarker (mI/Cr) ($R^2 = 0.753$) (Figure 3B). Weak or no correlation was observed for neuronal biomarker (NAA/Cr) and glial metabolic activity ($R^2 = 0.11$) (not shown).

Conclusions

Our preliminary results directly demonstrate progressively elevated glial metabolic rate in patients with MCI and AD in proportion to the elevation in glial marker myoinositol of conventional proton MRS, and inversely correlated with a clinical measure of cognitive decline, MMSE. Although the number of patients in this preliminary study is small, the data could contribute to the ongoing debate supporting the general belief that activation of glia observed in animal models, may occur in human MCI and AD.

Neuroscientists have made extensive use of the term ‘neuroinflammation’ to describe a complex process that occurs when glia cells undergo activation in response to stimuli such as viral infection, undesirable substances, injury, and illnesses. Activated microglia and glia cells have been reported in AD. It is possible that our observation of an increase in glial activation is synonymous with neuroinflammation. Additional studies are required to confirm that relationship. If confirmed, $^{13}$C MRS after infusion of $^{1-13}$C acetate as employed here would provide a practical approach to defining neuroinflammation in human brain. Extending the present observation to larger numbers of well-defined patients and in longitudinal studies which document the onset of glial hyperactivity in comparison with the earliest evidence of neuronal loss (proton MRS or $^{13}$C MRS using $^{1-13}$C glucose as exogenous substrate are valid techniques) could provide direct information on whether neuroinflammation is the immediate cause of MCI and AD or merely a secondary effect of neuronal injury. A conclusion in favor of the former mechanism would support the renewed impetus for preventative therapies, which target neuroinflammation in the increasing numbers of patients diagnosed with early AD. Human use of $^{13}$C MRS, as demonstrated here, is a safe, nonradioactive technique which can be performed on conventional clinical MRI scanners with only minor modification, and would be a valuable tool for such future studies.

Acknowledgment

The authors thank Norman Chien, MD for referral of AD subjects, Dr Michael Harrington, Ms Sherri Lee, and the Fuller Seminary students for their assistance in preliminary
subject screening (N = 3) and Mr Thomas Warren for his assistance in the infusion protocol. The study is funded by NIDA (K25DA21112, NS) and L.K. Whittier Foundation (BDR, KH, and TT).

Disclosure

The authors declare no conflicts of interest in this work.

References